The impact of stroma components on angiogenesis and Cancer Stem Cell (CSC) biology as a critical step in overcoming drug resistance is studied in WP3 using genetically engineered mouse models of pancreatic cancer (e.g. Hingorani et al 2003, Hingorani et al 2005, Guerra et al 2007) and xenografted human primary cancers (Sorio et al 2001). From a therapeutic perspective, WP3 elucidates the role of the inflammatory stroma in mediating resistance to anti-angiogenic and anti-proliferative pharmacological strategies and identifies potential therapeutic routes to target the inflammatory stroma to overcome drug resistance. Additionally, the role of CSCs in the progression of pancreatic cancer and resistance to therapeutics will be established, in order to identify new therapeutic vulnerabilities of CSCs.

WP lead:

Cancer Research UK, United Kingdom (CR-UK)

WP members:

Philipps-Universität Marburg, Germany (UNIMAR)
The University of Liverpool, United Kingdom (ULIV) per Participant
Fundación Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO)
University of Verona, Italy (UNIVR)
Ernst-Moritz-Arndt-Universität Greifswald, Germany (EMAU-G)
Karolinska Institute, Sweden (KI)
Technische Universität München, Klinikum rechts der Isar, Germany (TUM-MED)
Bayer Schering Healthcare, Germany (BSP)

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.